At the moment CAD is managed using off-label therapies, including rituximab and corticosteroid drugs, and sutimlimab's potential to improve treatment earned it a breakthrough designation from the FDA.

Background Coronary heart disease (CHD) remains a leading cause of mortality and disability worldwide. Approximately half of the patients who have had a prior hospital admission for CHD will have a ...